Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
However, the future of TKI combinations for these rare tumours is uncertain
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST